In patients with cardiovascular disease, par-experience has been gained in its use. Attention is now turning towards optimizing treatment in various subtial correction of anaemia with epoetin improves quality of life and exercise capacity, and reduces left groups of patients with CRF, divided according to either age or concomitant disease. This workshop ventricular hypertrophy. The currently recommended haemoglobin in these patients is 11-12 g/dl. The considered how epoetin might be used most effectively in: optimal haemoglobin in patients with diabetes mellitus does not differ from that in non-diabetic patients; $ patients with cardiovascular disease; however, haemoglobin should be increased slowly. $ patients with type 1 or type 2 diabetes mellitus; There is no difference in the recommended haemo-$ children; globin between children and adults. However, epoetin $ the elderly; sensitivity is lower in children who, therefore, typically $ patients with chronic obstructive pulmonary disneed the same absolute dose of epoetin as adults.
Introduction
ischaemic heart disease while patients were on dialysis. However, given the role of anaemia in promoting Epoetin has been used to treat the anaemia of chronic LVH, and the fact that LVH is strongly associated renal failure (CRF ) for more than a decade, and much with the de novo development of ischaemic heart disease, this finding may be a reflection of the small size Correspondence and offprint requests to: Professor Charles van of the group rather than the absence of any effect. the increased LV diastolic dimensions and the elevated the study was halted because of safety concerns and cardiac output that are characteristic of the anae-because it was considered that an attempt to prove mic uraemic state [4] . Increasing haemoglobin to benefit for the higher haematocrit group would be 11-12 g/dl has a beneficial effect on LVH within 6-12 futile. See C. Jacobs, this volume, for a discussion of months, though the heart does not return completely the results, as well as a recent commentary [18] , which to normal [5] [6] [7] [8] [9] . No prospective study has yet been discusses limitations and criticisms of the Normal carried out to determine whether this reduction in Hematocrit Cardiac Trial. LVH translates into a reduction in mortality.
Preliminary results from two recently completed In addition, it has been shown that correcting anae-trials, conducted in Canada and Scandinavia, indicated mia with epoetin improves exercise capacity and quality that normalization of haemoglobin did not have of life in CRF patients, including those with cardiovas-adverse cardiovascular effects. However, publication cular disease [10] .
of the full results is needed before any conclusions can A prospective analysis of data from the Lombardy be drawn on the benefits of normalizing haematocrit Registry [11] provides encouraging evidence for a in patients with cardiovascular disease. beneficial effect of epoetin on both general and cardioFurther studies are also needed to determine the vascular mortality. The results showed a statistically effects of epoetin treatment and haemoglobin on progsignificant progressive reduction in the relative risk of nosis in different subgroups of patients with ischaemic mortality up to the highest haematocrit, with or with-heart disease. For example, it would be interesting to out adjustment for co-morbid conditions. investigate possible differences between symptomatic In patients with pre-existing cardiovascular disease, and asymptomatic patients, or among different angioit is possible that the beneficial effects of epoetin on graphic and functional categories. the cardiovascular system might be offset by adverse
In the meantime, it seems prudent to recommend effects. For example, approximately one-third of that patients with ischaemic heart disease continue to patients treated with epoetin experience a significant be treated to a haemoglobin of 11-12 g/dl, as recomincrease in mean arterial blood pressure, although the mended by the National Kidney Foundation-Dialysis mechanism of this pressor response remains controver-Outcomes Quality Initiative (NKF-DOQITM ) [19] . sial [12] [13] [14] [15] . Other potential adverse effects on the cardiovascular system include increased blood viscosity Diabetes mellitus and an increased tendency towards thrombosis in polytetrafluoroethylene grafts.
Diabetes mellitus is the most common cause of endThe optimum haemoglobin for patients with existing stage renal disease ( ESRD). Overall, 16% of new cardiac disease has not yet been established. However, patients commencing renal replacement therapy in the linear relationship seen between the occurrence of Europe have diabetic nephropathy. Two-thirds of these congestive heart failure and haemoglobin as it declines patients have type 2 diabetes. Elderly patients account to <14 g/dl [16 ] suggests that there may be no 'threshfor a large proportion of new cases: between 1985 and old' haemoglobin for cardiac protection.
1995, there was a 10-to 20-fold increase in the subIt is possible that normalization of haemoglobin group of diabetic patients Á65 years of age [20, 21] . might provide the greatest benefits to CRF patients.
Compared with type 1 diabetes, renal damage in type The risks and benefits of normalizing the haematocrit 2 diabetes is associated with heterogeneous patterns of in patients with cardiac disease who were undergoing renal structural lesions [22, 23] . haemodialysis were examined in the Normal Whatever the method of renal replacement therapy, Hematocrit Cardiac Trial [17] . A total of 1233 haemosurvival rates for diabetic patients are lower than for dialysis patients with clinically evident congestive heart non-diabetic patients; most deaths are due to cardiofailure or ischaemic heart disease were included in the vascular disease. LVH is more prevalent in diabetic trial. Patients were randomized to one of two groups: compared with non-diabetic patients with ESRD, and a normal haematocrit group (n=618), in which it is possible that the beneficial effects of epoetin on patients received doses of epoetin sufficient to achieve LVH could be particularly relevant for diabetic and maintain a haematocrit of 42±3%, and a low patients [24] . haematocrit group (n=615), in which patients received To date, the effects of epoetin on peripheral vascular doses of epoetin sufficient to maintain a haematocrit disease and microangiopathic complications associated of 30±3%. The primary end point was time to death with diabetes have not been systematically assessed. or a first non-fatal myocardial infarction.
The possible benefits of an improved oxygen supply to The study was stopped prematurely after an interim target areas require further study. analysis at 29 months showed 183 deaths and 19 first Several case reports indicate that anaemia may non-fatal myocardial infarctions in patients randomdevelop in diabetic patients prior to renal failure (i.e. ized to the normal haematocrit group vs 150 deaths in patients with normal serum creatinine). It may and 14 first non-fatal myocardial infarctions in those therefore be helpful to identify and treat anaemia in randomized to the low haematocrit group (risk ratio such patients [25, 26 ] . normal vs low haematocrit: 1.3; 95% repeated confid-
The workshop panel concluded that, currently, there ence interval: 0.9-1.9). Although the difference in is no reason to recommend a different target haemoevent-free survival between the two groups did not reach the pre-specified statistical stopping boundary, globin for diabetic and non-diabetic patients; a haemo-globin of 11-12 g/dl is therefore also appropriate for treatment in children markedly reduces the need for blood transfusions, improves exercise tolerance and diabetic patients.
Nevertheless, attention must be paid to the rate at regresses LVH [31] .
Clinical experience in paediatric patients shows that, which the haemoglobin is increased in diabetic patients. These patients are particularly at risk of adverse effects with adequate iron supplementation, the subcutaneous (s.c.) and intravenous (i.v.) routes of epoetin adminisrelated to rapid expansion of the red cell mass and the impact of such expansion on blood volume and viscos-tration are equally efficacious. Today, epoetin is usually administered once weekly s.c. in children on peritoneal ity. Furthermore, glycosylation of epoetin can modify the epoetin clearance rate. The degree of metabolic dialysis and three times weekly i.v. in haemodialysed children. control in diabetic patients can therefore modify viscosity through its influence on osmolarity (changes in Children require absolute epoetin doses that are similar to those of adults [30, 32] . Thus, in relation to blood glucose) and on haemoglobin (changes in epoetin metabolism in body tissues) [24, 27, 28] . their body weight, the required doses in children are higher than in adults. Interestingly, the rise in haemoIncreases in peripheral vascular resistance and blood pressure, worsening of hypertension, vascular access globin is related to absolute dose and not to weightnormalized dose ( Figure 2 ). clotting and even seizures have been observed more frequently in diabetic dialysis patients when haemoMost paediatric patients report a subjective increase in appetite after initiation of epoetin treatment globin was increased too rapidly. A sudden increase in haemoglobin could also be particularly harmful to [29, [33] [34] [35] [36] [37] [38] , although no consistent changes have been found in either dietary intake of calories and proteins diabetic patients with microangiopathy, leading to further deterioration of circulation in the microvessels. or overall nutritional state in this patient group [29, [33] [34] [35] [36] [37] [38] [39] . Weight gain was observed in four trials While it is difficult to define what constitutes a 'slow' increase in haemoglobin, a suggested strategy is: (i) a studying the effects of epoetin in children [33, 35, 40, 41 ], yet no weight gain was seen in a further four trials cautious dosage of epoetin (initial dose of 2000 IU three times weekly, followed by increments of 2000 IU [36, 38, 42, 43] .
A growth-promoting effect has been reported during at monthly intervals); and (ii) careful adjustments of heparinization during dialysis [24, 27, 28] .
the correction of anaemic states of non-uraemic origin [44] . It has been hypothesized that epoetin treatment The haemoglobin should be measured at least once a week to determine the initial response. If haemo-could improve growth, which is often retarded in children with renal failure. An increase in growth globin increases by >1.3 g/dl (haematocrit >4%) over a 2 week period, the epoetin dose should be velocity was observed by Rees et al. in three prepubertal, but not in three pubertal, haemodialysis patients reduced. Once the target haemoglobin has been reached, the weekly dosage should be reduced and the [42] . In addition, Scharer et al. found an increase in height standard deviation score in two of six prepuberhaemoglobin monitored at regular intervals.
tal pre-dialysis patients [41] . However, the majority of studies, including two large multicentre trials [33,43],
Paediatric patients
have found no effect of epoetin on growth in terms of height. For example, Schaefer et al. [43] showed that epoetin did not affect height growth or bone maturaRenal anaemia in children can be corrected successfully tion over a treatment period of >1 year in 120 dialysed using epoetin, with a dose-dependent increase in haechildren. moglobin ( Figure 1 ) [29, 30] . As in adults, epoetin It has been argued that the partial correction of renal anaemia aimed for in all trials published so far may have been insufficient to demonstrate a growthpromoting effect. It is possible that better results might have been obtained with complete correction of renal anaemia. On the basis of the available evidence, however, the workshop participants concluded that if epoetin does affect growth, it probably does so in only a small proportion of children.
It is also interesting to note that correcting anaemia with epoetin before the onset of dialysis may delay the progression of CRF in children. Krmar et al. studied 11 anaemic children, aged 1.4-17.2 years, during 10-61 months of epoetin treatment [45] . The mean haemoglobin increased from 8.1 to 11.1 g/dl during therapy. The rate of deterioration of renal function was calculated by comparing the slopes of the regression lines of reciprocal serum creatinine values before and during to epoetin treatment (F. Schaefer, personal communication). Epoetin-induced hypertension is due mainly to volume expansion and increased peripheral vascular resistance.
The workshop concluded that the optimal haemoglobin in children and in adults should be the same (11-12 g/dl ). However, children typically will need the same absolute dose of epoetin as adults.
Elderly patients
Treatment of anaemia in elderly patients with CRF is more complex than in younger patients, due to the high prevalence of anaemia in this age group and the multiplicity of possible causes ( Table 1 ). In the UK, 20% of elderly women and 14% of men presenting to their general practitioner are anaemic [46 ] .
As anaemia in elderly CRF patients is often multifactorial, it is important to characterize the anaemia by examining red blood cell volume, reticulocyte counts and the appearance of the peripheral blood film.
Iron deficiency is encountered frequently in the elderly patient [47] , and is usually due to blood loss, especially from the gastrointestinal tract. An inadequate dietary supply of iron, as well as impaired absorption associated with gastric surgery, atrophic gastritis and intestinal malabsorption, may exacerbate This deficiency often results from an inability to separate vitamin B 12 from the R proteins in food, which is due to a lack of hydrochloric acid or pancreatic although the mean change of slope (from −0.0521 to −0.0299) was not significant. The authors concluded enzymes [47] . In~10% of elderly patients with vitamin B 12 deficiency, classical haematological, laboratory or that in most children with pre-dialysis CRF, long-term administration of epoetin may delay the deterioration clinical manifestations may be absent. All elderly CRF patients should therefore be screened for vitamin B 12 of renal function.
The major adverse effect observed during epoetin deficiency. Folate deficiency may also be present, as a result of treatment in children is arterial hypertension. Whilẽ 30% of paediatric dialysis patients require antihyper-malnutrition, excessive folate utilization, increased loss or malabsorption of folate by the body, or drugs tensive medication, this proportion increases to 50% of paediatric patients in the initial period of adaptation affecting folate metabolism. Red blood cell folate should be interpreted carefully because it may be misleadingly low in patients with vitamin B 12 deficiency and misleadingly high in patients with reticulocytosis or a recent blood transfusion.
Treatment of anaemia in elderly patients with CRF is therefore likely to include supplements necessary for normal erythropoiesis (e.g. iron, vitamin B 12 , folate), followed by epoetin therapy. Blood transfusion should be limited to patients with acute blood loss and patients with chronic anaemia that cannot be corrected by other means.
The suggestion that, even in the absence of complicating factors, the elderly patient might not respond as well to epoetin therapy as the younger patient [48] appears to be unfounded. No significant differences between induction and maintenance doses of epoetin, or in haemoglobin increment with duration of treat- 
Chronic obstructive pulmonary disease
had no influence on response to endogenous or exogenous erythropoietin. While maintenance dosages for epoetin are similar in elderly and younger patients, it In patients with CRF, erythropoietin concentrations are reduced due to impaired erythropoietin secretion. should be borne in mind that the response to epoetin must be monitored closely in any patient with compli-In contrast, polycythaemia has been reported in some patients with COPD, apparently as a result of enhanced cated anaemia as dosage requirements may be greater.
Compared with younger patients, the elderly CRF erythropoietin secretion in response to hypoxia. However, not all findings in COPD patients show an patient with uncomplicated anaemia will obtain a similar benefit from epoetin therapy in terms of haemo-unequivocal trend towards increased erythropoietin concentrations These divergent findings can be understood partly in terms of the multiple mechanisms that allow the between age and improvement in quality-of-life scores in patients receiving epoetin (Figure 4 ). Based on these body to adapt to chronic hypoxia [53], including oxygen-sensing devices, i.e. (i) the carotid bodies, results, the authors concluded that the use of epoetin in elderly patients is fully justified.
which sense the oxygen concentration in the blood; (ii) the Liljestrand-Euler mechanism in the lung, which There is no evidence that the optimal haemoglobin need be any lower in elderly than in younger redistributes blood flow to optimize oxygen uptake, and (iii) the erythropoietin-secreting mechanism in the patients. At present, a haemoglobin of 11-12 g/dl is recommended.
kidneys, which eventually enhances oxygen transport within the vascular system; and to other mechanisms, anaemia, cardiac output is usually high in patients i.e. (i) endothelial mechanisms, which induce the with sickle-cell disease, even at rest. formation of vascular endothelial growth factor Severe damage to the renal vasa rectae system occurs ( VEGF ); and (ii) intracellular mechanisms, which in most patients with sickle-cell anaemia, even in those optimize metabolic pathways to increase the energy with the otherwise harmless sickle-cell trait [57] . As a yield [54] .
consequence, ability to concentrate urine and to excrete COPD patients sometimes develop high haemato-acid loads is impaired. In older patients, there is a crits (>55%) as a result of both the continuous hypoxic tendency to glomerular fibrosis and obsolescence; the drive outlined above and a relative lowering of the result is a rapidly declining glomerular filtration rate plasma volume. Due to increased blood viscosity, and renal impairment, manifested by increasing serum convective transport within vessels >1 mm in diameter creatinine and declining haemoglobin. Ultimately, is impaired, although oxygen delivery in the capillaries ESRD and the need for renal replacement therapy remains unaffected. In this situation, according to the may develop [58] . literature, a haematocrit of 37-47% (haemoglobin of At present, only a minority of nephrologists have 12-15 g/dl ) allows optimal oxygen transport as well been faced with the problem of how to treat patients as optimal oxygen delivery within the capillaries [55] . with a combination of ESRD and sickle-cell disease. Plugging is prevented as long as the perfusion pressure In future, the problem is likely to become more remains sufficiently high and the white blood cell count common, as the survival of patients with sickle-cell remains within the normal range. disease improves, and more patients reach an age at In contrast, in CRF patients, it has been suggested which renal failure develops. that low haemoglobin concentrations do not impair
In steady-state sickle-cell disease, haemoglobin is oxygen delivery at the capillary level as long as suffi-typically between 6 and 9 g/dl. At these levels, most cient oxygen is transported. Oxygen transport is patients have adequate oxygen delivery, and classic enhanced through hypoxic vasodilatation [56 ] . The symptoms of anaemia are unusual. A high haemointerrelationship between the oxygen-transporting and globin, especially in the absence of a high fetal haemothe volume-regulating mechanisms in CRF requires globin, has been shown to be a risk factor for painful further investigation.
crises, hip necrosis, proliferative sickle retinopathy and, The effect of epoetin on peripheral tissues must still possibly, acute chest syndrome. These effects are probbe investigated. It is possible that epoetin-induced ably a result of increased blood viscosity [59, 60] . vasoconstriction only increases blood pressure and Painful crises, secondary to the sudden increase in reduces tissue perfusion. Alternatively, the volume haemoglobin, may also occur following splenectomy capacity of the total vascular system may be reduced, for hypersplenism and after successful renal transso that there is a beneficial increase in the filling plantation for renal failure. pressure of the heart. Progressive renal impairment is especially common A further issue to be explored is whether tissue in patients with sickle-cell anaemia who are over 40 hypoxia in the CRF patient leads to an activation of years of age. It is characterized by a gradually declining VEGF without adequate complementary erythropoi-haemoglobin secondary to reduced erythropoietin in etin secretion. If this were the case, vascularization of the blood [61] . Such patients frequently experience a the peripheral tissues would take place and plasma 'honeymoon period', since the declining haemoglobin volume would increase to fill the vascular bed protects against painful crises; the patient experiences adequately. Without an accompanying increase in fewer symptoms until the haemoglobin reaches a value red cell production, however, haemoglobin would which compromises cardiac function. At this point, decrease further.
which is usually associated with a haemoglobin of At present, there is no evidence on which to base 3-5 g/dl, reasonable health can be maintained by topadvice to physicians treating patients who have both up blood transfusions every 4-6 weeks, or as deter-CRF and COPD. In the absence of the necessary data, mined by patient demand. the workshop panel recommended that haemoglobin Alternatively, administration of epoetin could be in such patients be increased to 11 g/dl.
used to maintain haemoglobin and eliminate the need for transfusion. However, the determinants of the bone marrow response to epoetin in sickle-cell disease are
Sickle-cell disease
unknown, and near normal haemoglobin may precipitate painful crises. Moreover, the bone marrow is markedly expanded in sickle-cell disease, and response Sickle-cell disease is characterized by the presence of to epoetin in these patients is variable. In general, sickle haemoglobin (HbS). When deoxygenated, HbS doses needed to achieve a given increment in haemotends to polymerize into long chains, reducing the globin are more than in non-sickle-cell disease patients. flexibility of red cells and deforming many red blood On the basis of the available evidence, the workshop cells into the characteristic sickled shape. These red panel suggested that the haemoglobin in these patients blood cells are destroyed prematurely in the circulation, should not be increased above the pre-CRF value resulting in haemolytic features, such as anaemia, jaundice and gallstone formation. As a result of the (typically 6-9 g/dl ), in order to avoid painful crises.
Renal transplant patients
Renal transplant patients who could benefit from epoetin therapy can be divided into three main groups: pre-transplantation, early post-transplantation and failing or failed transplant. The effects of previous or concurrent epoetin treatment vary among these groups.
Pre-transplantation
Before the introduction of epoetin, most patients wait- failures and rejection episodes, but epoetin-treated In fact, available studies indicate that previous epopatients had a steeper increase in haemoglobin after etin treatment has no effect on rejection rate or graft transplantation and required fewer blood transfusions. survival [65] [66] [67] . Furthermore, previous epoetin treatHowever, it should be noted that the transfusion rate ment does not influence the incidence of renal allograft among the controls was unusually high in this study. thrombosis, a complication that ultimately leads to Further prospective trials are needed. graft loss [68] .
Results regarding immediate graft function are somewhat equivocal: two studies [65, 66 ] showed no Failing/failed renal transplant effect, while one showed a significant difference [67] .
The results of studies of a small number of patients Linde et al. with a failing transplant, but currently there is no [66 ] found no association between epoetin therapy cause for concern. during dialysis and delayed graft function. Resolution Most patients with failing or failed transplants of anaemia after transplantation was similar in the two respond to epoetin, although many require rather high groups, although the initial pattern of erythropoietin doses. This may be due to concomitant immunosecretion differed slightly between them.
suppressive treatment, in particular with azathioprine, Only one study, by Vasquez and Pollak [67], has inflammation or infection associated with the failing reported an increased incidence of delayed graft funcgraft, or the administration of other drugs, such as tion in 58 epoetin-treated patients compared with 62 angiotensin-converting enzyme inhibitors, angiotensin untreated controls (41% vs 18%, P<0.05). Rates of II receptor antagonists or theophylline. In patients acute rejection, time to first rejection or 1 year graft with a failed transplant who show resistance to epoetin, survival rate did not differ significantly between the transplant nephrectomy may improve response. two groups. This study has been criticized, however, on the grounds that some patients may have been dehydrated at the time of transplantation, with an Conclusions attendant variable effect on haemoglobin.
The recommendations of the workshop can be summarized as follows.
Early post-transplantation
It is interesting to speculate that epoetin might be $ The recommended optimum haemoglobin in patients with ischaemic heart disease is 11-12 g/dl. valuable in the early post-transplantation period. By lowering the need for blood transfusion, it could limit $ The optimal haemoglobin in patients with diabetes mellitus does not differ from that in non-diabetic the risk of human lymphocyte antigen sensitization and transmission of infection. Better oxygen delivery patients; however, haemoglobin should be increased slowly. to the graft might also lead to an improved outcome.
Only one prospective study has examined the effect $ There is no difference between the optimal haemoglobin recommended for children and for adults. of sustained administration of epoetin during the early post-transplantation period [69] . Epoetin-and non-
The increase in haemoglobin in children, however, 
